Key Points
- CEO Allan Marshall bought 100,000 shares at an average of $2.07 on Dec. 15 (plus 50,000 shares on Dec. 16), increasing his stake to 3,946,261 shares — a 2.6% rise valued at roughly $8.17 million.
- The Board has authorized a $50.0 million stock repurchase plan to buy up to 25.1% of outstanding shares, signaling the company may view the stock as undervalued.
- Upexi reported an EPS miss (‑$0.12 vs. ‑$0.01 expected) though revenue beat ($9.24M vs. $7.33M); shares traded around $1.98 midday with a market cap of ~$125M and a consensus "Hold" rating (average price target $10.50).
Upexi, Inc. (NASDAQ:UPXI - Get Free Report) CEO Allan Marshall bought 50,000 shares of the firm's stock in a transaction dated Tuesday, December 16th. The stock was purchased at an average price of $2.07 per share, for a total transaction of $103,500.00. Following the transaction, the chief executive officer owned 3,996,261 shares of the company's stock, valued at approximately $8,272,260.27. This represents a 1.27% increase in their ownership of the stock. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink.
Allan Marshall also recently made the following trade(s):
- On Monday, December 15th, Allan Marshall purchased 100,000 shares of Upexi stock. The shares were purchased at an average price of $2.07 per share, with a total value of $207,000.00.
Upexi Price Performance
UPXI stock traded up $0.15 during midday trading on Thursday, reaching $2.02. The stock had a trading volume of 1,620,039 shares, compared to its average volume of 4,136,309. Upexi, Inc. has a 52-week low of $1.86 and a 52-week high of $22.57. The company has a market cap of $127.37 million, a price-to-earnings ratio of -0.47 and a beta of -0.52. The company's fifty day simple moving average is $3.69 and its 200 day simple moving average is $5.73. The company has a current ratio of 3.41, a quick ratio of 3.39 and a debt-to-equity ratio of 0.68.
Upexi (NASDAQ:UPXI - Get Free Report) last issued its earnings results on Wednesday, November 12th. The company reported ($0.12) EPS for the quarter, missing analysts' consensus estimates of ($0.01) by ($0.11). The business had revenue of $9.24 million during the quarter, compared to analyst estimates of $7.33 million. Upexi had a net margin of 264.25% and a negative return on equity of 30.42%.
Upexi declared that its board has authorized a share buyback program on Thursday, November 13th that allows the company to repurchase $50.00 million in outstanding shares. This repurchase authorization allows the company to purchase up to 25.1% of its shares through open market purchases. Shares repurchase programs are generally a sign that the company's board of directors believes its stock is undervalued.
Analysts Set New Price Targets
Several research analysts have recently weighed in on the company. Weiss Ratings restated a "sell (d+)" rating on shares of Upexi in a report on Monday. Wall Street Zen raised Upexi from a "sell" rating to a "hold" rating in a research note on Tuesday. Finally, Cantor Fitzgerald dropped their target price on Upexi from $16.00 to $6.00 and set an "overweight" rating for the company in a report on Friday, November 14th. Two research analysts have rated the stock with a Buy rating and one has issued a Sell rating to the stock. According to data from MarketBeat.com, the company currently has a consensus rating of "Hold" and a consensus target price of $10.50.
Read Our Latest Stock Report on UPXI
Institutional Trading of Upexi
Several institutional investors have recently made changes to their positions in the company. Ameritas Advisory Services LLC purchased a new position in Upexi in the third quarter worth approximately $26,000. North Star Investment Management Corp. acquired a new position in shares of Upexi in the 2nd quarter valued at $45,000. Belpointe Asset Management LLC purchased a new position in shares of Upexi during the 3rd quarter worth $58,000. Arkadios Wealth Advisors purchased a new position in shares of Upexi during the 3rd quarter worth $58,000. Finally, Millington Financial Advisors LLC acquired a new stake in shares of Upexi during the 2nd quarter worth about $60,000. Hedge funds and other institutional investors own 5.68% of the company's stock.
About Upexi
(
Get Free Report)
Upexi, Inc manufactures and sells various branded products in the health, wellness, pet, beauty, and other markets. The company was formerly known as Grove, Inc and changed its name to Upexi, Inc in August 2022. The company was incorporated in 2018 and is headquartered in Clearwater, Florida.
Featured Stories
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
